OBJECTIVE: In the vitamin D receptor (VDR) gene a BsmI restriction fragment length polymorphism (RFLP) in intron 8 and a translational start-site polymorphism, identified as a FokI RFLP, have been described. Crucial for a proper interpretation of these polymorphisms in association studies is the knowledge whether they have direct consequences for 1,25-(OH)2D3 action at cellular level. The present study was designed to assess functional significance of the FokI and BsmI VDR gene polymorphisms in peripheral blood mononuclear cells (PBMC) with a natural occurring VDR genotype for cell growth inhibition by 1,25-(OH)2D3. DESIGN: PBMC of women were isolated, VDR genotyped and in vitro inhibition by 1,25-(OH)2D3 of Phytohemagglutinin (PHA)-stimulated growth of PBMC was examined in relation to VDR genotype. RESULTS: PHA-stimulated growth and maximal growth inhibition were independent of VDR genotype. However, the FF genotype had a significant lower ED50 than the Ff genotype corresponding to an allele dose effect of 0.32 nM per f allele copy (P = 0.0036). For BsmI genotypes no differences in ED50 were observed. CONCLUSION: The present study demonstrates for the first time in cells with a natural VDR genotype a direct functional consequence of the VDR gene translational start-site polymorphism for the action of 1,25-(OH)2D3. Especially under conditions of vitamin D insufficiency these findings might have clinical implications.
OBJECTIVE: In the vitamin D receptor (VDR) gene a BsmI restriction fragment length polymorphism (RFLP) in intron 8 and a translational start-site polymorphism, identified as a FokI RFLP, have been described. Crucial for a proper interpretation of these polymorphisms in association studies is the knowledge whether they have direct consequences for 1,25-(OH)2D3 action at cellular level. The present study was designed to assess functional significance of the FokI and BsmI VDR gene polymorphisms in peripheral blood mononuclear cells (PBMC) with a natural occurring VDR genotype for cell growth inhibition by 1,25-(OH)2D3. DESIGN: PBMC of women were isolated, VDR genotyped and in vitro inhibition by 1,25-(OH)2D3 of Phytohemagglutinin (PHA)-stimulated growth of PBMC was examined in relation to VDR genotype. RESULTS: PHA-stimulated growth and maximal growth inhibition were independent of VDR genotype. However, the FF genotype had a significant lower ED50 than the Ff genotype corresponding to an allele dose effect of 0.32 nM per f allele copy (P = 0.0036). For BsmI genotypes no differences in ED50 were observed. CONCLUSION: The present study demonstrates for the first time in cells with a natural VDR genotype a direct functional consequence of the VDR gene translational start-site polymorphism for the action of 1,25-(OH)2D3. Especially under conditions of vitamin Dinsufficiency these findings might have clinical implications.
Authors: Ivone F O C Nunes; Ana A C M Cavalcante; Marcus V O B Alencar; Marcos D F Carvalho; José L R Sarmento; Nayra S C C A Teixeira; Adriana A Paiva; Lídia R Carvalho; Leopoldo F M Nascimento; Maria S P Cruz; Marcelo M Rogero; Andréia C B Lima; Cecilia M R G Carvalho Journal: Adv Nutr Date: 2020-09-01 Impact factor: 8.701
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Michael E Carney; Rachel T Palmieri; Paul D P Pharoah; Honglin Song; Estrid Hogdall; Susanne Kruger Kjaer; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Marc T Goodman Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396
Authors: P Selvaraj; G Chandra; M S Jawahar; M Vidya Rani; D Nisha Rajeshwari; P R Narayanan Journal: J Clin Immunol Date: 2004-09 Impact factor: 8.317
Authors: Juliette A Randerson-Moor; John C Taylor; Faye Elliott; Yu-Mei Chang; Samantha Beswick; Kairen Kukalizch; Paul Affleck; Susan Leake; Sue Haynes; Birute Karpavicius; Jerry Marsden; Edwina Gerry; Linda Bale; Chandra Bertram; Helen Field; Julian H Barth; Isabel Dos Santos Silva; Anthony Swerdlow; Peter A Kanetsky; Jennifer H Barrett; D Timothy Bishop; Julia A Newton Bishop Journal: Eur J Cancer Date: 2009-07-15 Impact factor: 9.162
Authors: S Tamez; C Norizoe; K Ochiai; D Takahashi; A Shimojima; Y Tsutsumi; N Yanaihara; T Tanaka; A Okamoto; M Urashima Journal: Br J Cancer Date: 2009-11-10 Impact factor: 7.640